Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Mark Nordlicht, Platinum Management Increase Holding of Echo Therapeutics Inc (ECTE)

Mark A. Nordlicht and Platinum Management have upped their holding of Echo Therapeutics Inc (NASDAQ:ECTE) shares. In a recent filing with the Securities and Exchange Commission, Platinum Management disclosed the acquisition of 69,569 shares in two transactions at a price of $2.75 apiece. As a result, Platinum currently holds 578,452 shares worth approximately $2 million at current market prices.

Echo Therapeutics Inc (ECTE)

Jim Simons shares Nordlicht’s optimism about Echo Therapeutics Inc (NASDAQ:ECTE). Renaissance Technologies has more than doubled its stake during the third quarter of 2013 and now owns 123,587 shares valued at $341,000. Fred Knoll has a different opinion, with his fund, Knoll Capital Management, dumping 90% of their holding of Echo Therapeutics. As a result, the fund now holds only 44,445 shares reportedly worth $123,000. Trellus Management Company, run by Adam Usdan, and Donald Chiboucis‘ Columbus Circle Investors have liquidated their position during the third quarter.

Echo Therapeutics Inc (NASDAQ:ECTE) is a drug manufacturer operating in the United States. The stock has been in a downtrend most of 2013 and has slumped 68%. With a current share price of $3.43, the company has a market cap of $36.2 million and has a beta of 0.07. Echo Therapeutics does not pay a dividend. For the three months ended September 30, the company reported revenues of $22,557 and net loss of $5.2 million, which translates into a loss per share of $0.49. Analysts are not too optimistic about this quarter either. They expect revenues of $20,000 and a loss of $0.4 per share.

On December 10, 2013, Echo Therapeutics Inc (NASDAQ:ECTE) announced a strategic partnership with Medical Technologies Innovation Asia. Robert F. Doman, Executive Chairman and Interim Chief Executive Officer, said:

We are excited to be working with MTIA in this new relationship to meet the growing glucose monitoring needs in China. We believe MTIA’s expertise and relationships in China will enhance Echo’s success in this region and our overall value proposition.

Disclosure: none

Recommended reading:

Blue Harbour Group Further Increase Their Stake in CACI International Inc (CACI)

Roumell Asset Management Further Limits Exposure to Transcept Pharmaceuticals Inc (TSPT)

Spo Advisory Sells Some More Petroquest Energy Inc (PQ) Shares

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.